UB Paderborn / Katalog / Suche / in CDI

Es ist ein Fehler in der Kommunikation mit einem externen System aufgetreten. Bitte versuchen Sie Ihre letzte Aktion erneut. Sollte der Fehler bestehen bleiben, setzen Sie sich bitte mit dem Informationszentrum der Bibliothek in Verbindung oder versuchen Sie es später erneut.

1 – 25 von 192

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents

Journal of clinical oncology, 2006-04, Vol.24 (10), p.1633-1642

2006

Volltextzugriff (PDF)

Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials

Cancer, 2003-06, Vol.97 (11), p.2869-2879

2003

Volltextzugriff (PDF)

Ductal Carcinoma In Situ, Complexities and Challenges

JNCI : Journal of the National Cancer Institute, 2004-06, Vol.96 (12), p.906-920

2004

Volltextzugriff (PDF)

Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer

Journal of clinical oncology, 2006-02, Vol.24 (5), p.769-777

2006

Volltextzugriff (PDF)

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

Journal of clinical oncology, 2005-11, Vol.23 (31), p.7811-7819

2005

Volltextzugriff (PDF)

Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials

JOURNAL OF CLINICAL ONCOLOGY, 2023, Vol.41 (16_suppl), p.503-503

2023

Volltextzugriff (PDF)

Abstract OT3-03-01: Increasing participation in research - Breast cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.OT3-03-01-OT3-03-01

2016

Volltextzugriff (PDF)

Tall tales from sly dwarves: novel functions of gibberellins in plant development

Trends in plant science, 2005-03, Vol.10 (3), p.123-129

2005

Volltextzugriff (PDF)

Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials

JOURNAL OF CLINICAL ONCOLOGY, 2023, Vol.41 (16_suppl), p.508-508

2023

Volltextzugriff (PDF)

Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells

The Journal of clinical investigation, 2003-01, Vol.111 (1), p.81-90

2003

Volltextzugriff (PDF)

6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

Breast (Edinburgh), 2024-08, Vol.76, p.103756, Article 103756

2024

Volltextzugriff (PDF)

Long-Term Follow-Up for Locally Advanced and Inflammatory Breast Cancer Patients Treated With Multimodality Therapy

Journal of clinical oncology, 2004-10, Vol.22 (20), p.4067-4074

2004

Volltextzugriff (PDF)

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2726-2734

2005

Volltextzugriff (PDF)

Abstract PD8-04: Racial differences in the molecular landscape of breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.PD8-04-PD8-04

2017

Volltextzugriff (PDF)

Abstract PD6-03: Distribution of microsatellite instability, tumor mutational load, and PD-L1 status in molecularly profiled invasive breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD6-03-PD6-03

2018

Volltextzugriff (PDF)

The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review

Journal of cancer research and clinical oncology, 2004, Vol.130 (1), p.1-7

2004

Volltextzugriff (PDF)

Gibberellins Are Required for Seed Development and Pollen Tube Growth in Arabidopsis

The Plant cell, 2002-12, Vol.14 (12), p.3133-3147

2002

Volltextzugriff (PDF)

Abstract OT3-04-01: Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: The OXEL study

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-04-01-OT3-04-01

2019

Volltextzugriff (PDF)

Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

Clinical cancer research, 2013-07, Vol.19 (13), p.3681-3692

2013

Volltextzugriff (PDF)

Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Journal of clinical oncology, 2004-08, Vol.22 (15), p.3080-3090

2004

Volltextzugriff (PDF)

Abstract P5-09-04: Consensus and disagreement between experts and community practitioners asked to make therapeutic recommendations for early breast cancer (EBC)

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P5-P5-09-04

2016

Volltextzugriff (PDF)

Development of Novel Chemotherapeutic Agents to Evade the Mechanisms of Multidrug Resistance (MDR)

Seminars in oncology, 2005-12, Vol.32 (6 Suppl 7), p.22-26

2005

Volltextzugriff (PDF)

Abstract P4-21-41: Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-41

2017

Volltextzugriff (PDF)

Abstract P5-20-04: Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated results from the BERENICE study

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-20-04

2018

Volltextzugriff (PDF)

Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS1-02-GS1-02

2018

Volltextzugriff (PDF)

1 – 25 von 192

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(180)
Mit Volltextzugriff
(166)

Publikationsform

Artikel
(177)
Tagungsberichte
(15)

Sprache

Englisch
(192)

Erscheinungsjahr

n.n

Thema

Science & Technology
(153)
Life Sciences & Biomedicine
(124)
Humans
(77)
Biological And Medical Sciences
(69)
Female
(66)
Oncology
(49)
Medical Sciences
(48)
Breast Neoplasms - Drug Therapy
(38)
Animals
(34)
Adult
(32)
Middle Aged
(32)
Pharmacology. Drug Treatments
(28)
Breast Neoplasms - Pathology
(24)
Aged
(21)
Antineoplastic Agents
(21)
Fundamental And Applied Biological Sciences. Psychology
(21)
Male
(20)
Physical Sciences
(20)
Plant Sciences
(19)
Chemotherapy
(18)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents

Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials

Ductal Carcinoma In Situ, Complexities and Challenges

Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials

Abstract OT3-03-01: Increasing participation in research - Breast cancer

Tall tales from sly dwarves: novel functions of gibberellins in plant development

Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials

Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells

6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

Long-Term Follow-Up for Locally Advanced and Inflammatory Breast Cancer Patients Treated With Multimodality Therapy

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer

Abstract PD8-04: Racial differences in the molecular landscape of breast cancer

Abstract PD6-03: Distribution of microsatellite instability, tumor mutational load, and PD-L1 status in molecularly profiled invasive breast cancer

The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review

Gibberellins Are Required for Seed Development and Pollen Tube Growth in Arabidopsis

Abstract OT3-04-01: Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: The OXEL study

Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Abstract P5-09-04: Consensus and disagreement between experts and community practitioners asked to make therapeutic recommendations for early breast cancer (EBC)

Development of Novel Chemotherapeutic Agents to Evade the Mechanisms of Multidrug Resistance (MDR)

Abstract P4-21-41: Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

Abstract P5-20-04: Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated results from the BERENICE study

Suchergebnisse filtern